Replimune Group, Inc. (REPL) Stock Analysis and Metrics

Replimune

NASDAQ: REPL

$9.69 ▼ -0.77 (-7.31%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap904.37 Mn

P/E-2.88

Div. Yield0.00

ROIC (Qtr)-0.03

Total Debt (Qtr)83.31 Mn

Add ratio to table…

About

Replimune Group Inc is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies to treat cancer. The company leverages its proprietary RPx platform based on an engineered strain of herpes simplex virus 1 to create product candidates designed to selectively replicate in tumors, kill cancer cells, and stimulate a systemic anti-tumor immune response. Its approach combines direct oncolytic activity with immune activation to enhance the body's natural defenses against cancer, particularly in combination with immune checkpoint blockade therapies.

Replimune Group Inc generates revenue primarily through potential future sales of its product candidates upon regulatory approval and commercialization. The company currently has no approved products and does not generate product revenue. Its financial support comes from collaboration agreements, such as those with Bristol Myers Squibb and Roche, which provide therapeutic agents like nivolumab, atezolizumab, and bevacizumab at no cost for use in clinical trials. Additionally, the company relies on funding from public and private capital markets to support its research, development, and operational activities.

The company operates through the following segments:

• RP1 (vusolimogene oderparepvec) is the lead product candidate, based on an engineered HSV-1 strain expressing GALV-GP R(-) and human GM-CSF. It is being developed for the treatment of advanced melanoma, non-melanoma skin cancers, and skin cancers in solid organ transplant recipients. RP1 is administered via direct tumor injection and is being evaluated both as a monotherapy and in combination with nivolumab. Key clinical trials include the IGNYTE trial for anti-PD-1 failed melanoma, the IGNYTE-3 (I-3) trial as a confirmatory Phase 3 study, the ARTACUS trial in transplant recipients with skin cancer, and ongoing enrollment in the non-melanoma skin cancer cohort of the IGNYTE trial.

• RP2 is a second product candidate engineered to express an antibody-like molecule that blocks CTLA-4, in addition to GALV-GP R(-) and human GM-CSF. It is being developed for metastatic uveal melanoma and hepatocellular carcinoma, with clinical activity observed in difficult-to-treat tumors. RP2 is being evaluated in the REVEAL study, a randomized phase 2/3 trial comparing RP2 plus nivolumab to ipilimumab plus nivolumab in immune checkpoint inhibitor-naive metastatic uveal melanoma patients. It is also being studied in combination with atezolizumab and bevacizumab for hepatocellular carcinoma in collaboration with Roche.

• RP3 is a third product candidate designed to express ligands for CD40 and 4-1BBL pathways, along with anti-CTLA-4 and GALV-GP R(-), but without GM-CSF. It is intended to further stimulate T-cell activation and anti-tumor immune responses. Due to program prioritization, further development of RP3 is not currently being pursued.

Replimune Group Inc operates in the highly competitive biotechnology and pharmaceutical industry, specifically within the oncology and immunotherapy sectors. The company faces competition from large biopharmaceutical firms with greater financial and manufacturing resources, as well as from other companies developing oncolytic viruses, immune checkpoint inhibitors, cancer vaccines, and cell-based therapies such as CAR-T and TILs. Its competitive advantages lie in its proprietary RPx platform, which combines multiple mechanisms of action in a single off-the-shelf product candidate, its intellectual property portfolio including issued patents in the U. S., Europe, Japan, and other jurisdictions, and its in-house manufacturing facility in Framingham, Massachusetts, which supports control over supply chain and production timelines.

Replimune Group Inc serves patients with advanced melanoma, metastatic uveal melanoma, hepatocellular carcinoma, and various skin cancers including cutaneous squamous cell carcinoma, Merkel cell carcinoma, basal cell carcinoma, and angiosarcoma. The company also focuses on solid organ transplant recipients who develop skin cancers due to immunosuppressive therapies. Its product candidates are intended for use in clinical settings where tumors can be accessed via direct injection, guided by imaging techniques such as ultrasound or computerized tomography, and are designed to complement existing treatment regimens including immune checkpoint blockade therapies.

Investment Thesis

▲ Bull case

Replimune's upcoming resubmission of its melanoma drug RP1 represents a critical inflection point driven by a fundamental shift in FDA leadership and regulatory alignment, which the market may be underestimating despite recent volatility. The company explicitly states it and the FDA are now aligned on a path forward, with the agency indicating it will treat the application as an urgent matter and prioritize review—a significant departure from prior rejections that cited insufficient data from single-arm studies. This alignment suggests the FDA may have revised its evidentiary expectations or is now more receptive to accelerated approval pathways for therapies addressing high unmet need in advanced melanoma, particularly given the estimated 112,000 new U.S. cases and 8,510 deaths annually. The prior rejections were not based on safety concerns but on trial design disagreements, and Replimune’s commitment to initiating a late-stage confirmatory trial to satisfy regulatory requirements demonstrates a proactive, science-driven approach rather than mere persistence. The drug’s mechanism as an oncolytic immunotherapy using a genetically modified herpes virus offers a distinct biological advantage in stimulating anti-tumor immunity, potentially overcoming resistance to existing PD-1 inhibitors like Opdivo, and its combination with Bristol Myers Squibb’s Opdivo leverages a proven backbone therapy. Furthermore, the White House’s reported intervention—framed around the Trump administration’s push to accelerate access for terminally ill patients—adds political tailwinds that could expedite review, especially with the departure of Commissioner Makary, whose leadership was marked by contentious disputes with drugmakers over perceived inconsistent guidance. The market’s reaction to the news—shares spiking up to 86% in a single day—reflects skepticism rooted in past failures, but the combination of renewed regulatory dialogue, a clear path to generating confirmatory data, and the drug’s differentiated mechanism positions RP1 for potential approval where prior attempts failed, creating asymmetric upside if the resubmission succeeds.

Replimune's upcoming resubmission of its melanoma drug RP1 represents a critical inflection point driven by a fundamental shift in FDA leadership and regulatory alignment, which the market may be underestimating despite recent volatility. The company explicitly states it and the FDA are now aligned on a path forward, with the agency indicating it will treat the application as an urgent matter and prioritize review—a significant departure from prior rejections that cited insufficient data from single-arm studies. This alignment suggests the FDA may have revised its evidentiary expectations or is now more receptive to accelerated approval pathways for therapies addressing high unmet need in advanced melanoma, particularly given the estimated 112,000 new U.S. cases and 8,510 deaths annually. The prior rejections were not based on safety concerns but on trial design disagreements, and Replimune’s commitment to initiating a late-stage confirmatory trial to satisfy regulatory requirements demonstrates a proactive, science-driven approach rather than mere persistence. The drug’s mechanism as an oncolytic immunotherapy using a genetically modified herpes virus offers a distinct biological advantage in stimulating anti-tumor immunity, potentially overcoming resistance to existing PD-1 inhibitors like Opdivo, and its combination with Bristol Myers Squibb’s Opdivo leverages a proven backbone therapy. Furthermore, the White House’s reported intervention—framed around the Trump administration’s push to accelerate access for terminally ill patients—adds political tailwinds that could expedite review, especially with the departure of Commissioner Makary, whose leadership was marked by contentious disputes with drugmakers over perceived inconsistent guidance. The market’s reaction to the news—shares spiking up to 86% in a single day—reflects skepticism rooted in past failures, but the combination of renewed regulatory dialogue, a clear path to generating confirmatory data, and the drug’s differentiated mechanism positions RP1 for potential approval where prior attempts failed, creating asymmetric upside if the resubmission succeeds.

▼ Bear case

Replimune faces substantial and unresolved risks in its quest for RP1 approval that the market may be overlooking amid the enthusiasm surrounding the FDA leadership change, particularly the persistent lack of robust clinical evidence from controlled trials. Despite the company’s assertion of alignment with the FDA, the core issue remains unchanged: RP1’s efficacy data still derives primarily from single-arm studies without a control group, which the FDA has repeatedly and explicitly stated is insufficient for substantial evidence of effectiveness under regulatory standards, as emphasized by former Commissioner Makary and reinforced by career scientists at HHS who unanimously determined the evidence does not meet approval thresholds. The company’s plan to initiate a late-stage confirmatory trial only after resubmission introduces significant execution risk, as approval would likely be contingent on future trial outcomes, meaning any near-term approval would likely be accelerated or conditional—subject to potential withdrawal if confirmatory data fails to materialize, creating a binary outcome heavily dependent on uncertain future results. Furthermore, the melanoma therapeutics landscape is increasingly competitive, with FDA-approved alternatives like Iovance’s Amtagvi (a T-cell therapy) already capturing market share in the same advanced melanoma setting, and Bristol Myers Squibb’s Opdivo—while used in combination—faces diminishing returns as monotherapy efficacy plateaus, reducing the incremental value RP1 might add. The drug’s commercial viability is further undermined by Replimune’s deteriorating financial position, evidenced by the CEO’s announcement of job cuts and scaled-back U.S. manufacturing following the second rejection, signaling cash constraints that could limit the company’s ability to fund the required confirmatory trial or sustain operations through a prolonged review process. Even if approved, RP1 would enter a market where patients have limited tolerance for complex regimens, and the need for intralesional administration (injected directly into tumors) poses logistical and adherence challenges compared to systemic therapies. Finally, the reliance on White House intervention and political pressure introduces regulatory uncertainty, as any approval perceived as influenced by non-scientific factors could invite future scrutiny, legal challenges, or reversals under subsequent administrations, making long-term investor confidence fragile despite short-term optimism.

Replimune faces substantial and unresolved risks in its quest for RP1 approval that the market may be overlooking amid the enthusiasm surrounding the FDA leadership change, particularly the persistent lack of robust clinical evidence from controlled trials. Despite the company’s assertion of alignment with the FDA, the core issue remains unchanged: RP1’s efficacy data still derives primarily from single-arm studies without a control group, which the FDA has repeatedly and explicitly stated is insufficient for substantial evidence of effectiveness under regulatory standards, as emphasized by former Commissioner Makary and reinforced by career scientists at HHS who unanimously determined the evidence does not meet approval thresholds. The company’s plan to initiate a late-stage confirmatory trial only after resubmission introduces significant execution risk, as approval would likely be contingent on future trial outcomes, meaning any near-term approval would likely be accelerated or conditional—subject to potential withdrawal if confirmatory data fails to materialize, creating a binary outcome heavily dependent on uncertain future results. Furthermore, the melanoma therapeutics landscape is increasingly competitive, with FDA-approved alternatives like Iovance’s Amtagvi (a T-cell therapy) already capturing market share in the same advanced melanoma setting, and Bristol Myers Squibb’s Opdivo—while used in combination—faces diminishing returns as monotherapy efficacy plateaus, reducing the incremental value RP1 might add. The drug’s commercial viability is further undermined by Replimune’s deteriorating financial position, evidenced by the CEO’s announcement of job cuts and scaled-back U.S. manufacturing following the second rejection, signaling cash constraints that could limit the company’s ability to fund the required confirmatory trial or sustain operations through a prolonged review process. Even if approved, RP1 would enter a market where patients have limited tolerance for complex regimens, and the need for intralesional administration (injected directly into tumors) poses logistical and adherence challenges compared to systemic therapies. Finally, the reliance on White House intervention and political pressure introduces regulatory uncertainty, as any approval perceived as influenced by non-scientific factors could invite future scrutiny, legal challenges, or reversals under subsequent administrations, making long-term investor confidence fragile despite short-term optimism.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password